PECAM1 and neoplasm: Although direct evidence linking CIP2A modulation to changes in CD31 and p-AMPK in lung cancer is limited, the cumulative data on AKT activation, E-cadherin regulation, and tumor progression support the hypothesis that CIP2A promotes angiogenesis and suppresses metabolic regulation.